LITTLE KNOWN FACTS ABOUT INTERLEUKIN-2 THERAPY.

These increasing cells had been distinguished from rising B cells through the absence of EBV, which could market the very long-time period development of B cells. These results were being speedily followed by studies, equally in mice and human beings, demonstrating that supernatants derived from lectin-stimulated standard lymphocytes could sustain